| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PRIMA-1-Met | CTRPv2 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | NVP-231 | CTRPv2 | pan-cancer | AAC | -0.0029 | 0.9 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | 0.005 | 0.9 |
| mRNA | ceranib-2 | CTRPv2 | pan-cancer | AAC | -0.0029 | 0.9 |
| mRNA | Carboplatin | CTRPv2 | pan-cancer | AAC | 0.0032 | 0.9 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | -0.0028 | 0.9 |
| mRNA | KX2-391 | CTRPv2 | pan-cancer | AAC | 0.0027 | 0.9 |
| mRNA | HC-067047 | CTRPv2 | pan-cancer | AAC | 0.0031 | 0.9 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0029 | 0.9 |
| mRNA | GMX-1778 | CTRPv2 | pan-cancer | AAC | -0.0026 | 0.9 |